At its annual Investors’ Day being held today in Paris, SCOR presents updated information and analyses demonstrating that the Group is consistently delivering on its promises and is in a perfect position to seize new

At its annual Investors’ Day being held today in Paris, SCOR presents updated information and analyses demonstrating that the Group is consistently delivering on its promises and is in a perfect position to seize new

Winner of the Actuarial Award in UK, 2012

SCOR records net income of EUR 318 million for the first nine months of 2012, confirming the strength of its business model.

SCOR records net income of EUR 318 million for the first nine months of 2012, confirming the strength of its business model.

SCOR records net income of EUR 318 million for the first nine months of 2012, confirming the strength of its business model

Winner of the Actuarial Award in Germany, 2012

In a challenging environment, SCOR meets its targets and records net income of EUR 206 million in the first half 2012

In a challenging environment, SCOR meets its targets and records net income of EUR 206 million in the first half 2012.

Mémoire présenté par Sébastien de Valeriola en vue de l’obtention du master en sciences actuarielles (juin 2012).

Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.

Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.